Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Lifestyle Drugs Market by Therapeutic Type (Obesity, Women’s Health, Insomnia, Sexual Dysfunction, Dermatology, Others), by Form (Tablets, Gel, Oral Syrups, Parenteral, Creams, Chewing Gums) and by Distribution Channel (Hospital Pharmacy, Drug Store, Retail Store, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

A13368

Pages: NA

Charts: NA

Tables: NA

Lifestyle drugs are the type of medications used in the treatment of non-threatening and non-painful condition such as baldness, erectile dysfunction, acne, and others. Non-medical problems and minor medical conditions can be treated with help of this drugs. Main goal of this drug is to improve quality of life and maintain healthy lifestyle. Moreover, these drugs are used in eliminating the chronic life style habits such as alcohol and smoking consumption. Hair loss reduction agents, smoking withdrawal, fat burner, anti-wrinkle drugs, and others are the types of lifestyle drugs.

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the lifestyle drugs market.

Top Impacting Factors

  • Surge in adoption of healthy lifestyle all over the globe, increase in skin related disorders such as skin infection, rise in demand for topical dermatology drugs, surge in consumption of alcohol & cigarettes, and increase in geriatric population are the key factors that drive the growth of the market.
  • In addition, rise in expenditure on personal care products, surge in demand of disorder specific treatment, increase in expenses on health care sector, R & D activities to improve quality of drugs, government support to spread awareness to stop consumption of alcohol & smoking, and ongoing development of personalized lifestyle drugs by key market players are some factors, that drive the growth of the market.
  • However, side effects related to lifestyle drugs can hinder the growth of the market.
  • Contrarily, rise in popularity of lifestyle drugs due to e-commerce development are expected to offer lucrative opportunities for the expansion of the market.

Market Trends

New Product Launches to Flourish the Market

In 2021, Pacific Nature announced launch of vitamin and supplement product launch. This product is named as EpiCor which help to fulfil daily requirement of vitamins and minerals.

In 2021 Huel launched vegan protein powder. This powder is word’s first complete nutritional vegan protein powder which help to fulfil daily requirement of protein in vegan population.

In 2019, Dr. Reddy’s announced launch of Tadalafil product in U.S. market. This drugs is used in treatment of erectile dysfunction.

In 2018, Glenmark announced launch of hair loss treatment product named as Nourkrin in Russia. This product is used to stop hair loss in adults & aged persons.

Key Benefits of the Report

  • This study presents the analytical depiction of lifestyle drugs market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Lifestyle Drugs Market Report                           

  • Which are the leading players active in the lifestyle drugs market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "lifestyle drugs"?
  • What is "lifestyle drugs" market prediction in the future?
  • Who are the leading global players in the "lifestyle drugs" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "lifestyle drugs" market report?

 Key Market Segments

  • By Therapeutic Type
    • Obesity
    • Women’s Health
    • Insomnia
    • Sexual Dysfunction
    • Dermatology
    • Others
  • By Form
    • Tablets, Gel
    • Oral Syrups
    • Parenteral
    • Creams
    • Chewing Gums
  • By Distribution Channel
    • Hospital Pharmacy
    • Drug Store
    • Retail Store
    • Online Pharmacy
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Biocon Limited
  • Allergan
  • Amgen Inc.
  • Sanofi
  • Valeant Pharmaceuticals
  • Eli Lilly
  • Pfizer
  • Dr. Reddy's Laboratories.
  • AstraZeneca,
  • Merck
  • Teva Pharmaceutical Industries Ltd.
  • Johnson and Johnson
  • BMS
  • Galderma
  • Novartis

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: LIFESTYLE DRUGS MARKET, BY THERAPEUTIC TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Therapeutic Type

    • 4.2. Obesity

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Women’s Health

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Insomnia

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Sexual Dysfunction

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Dermatology

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Others

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

  • CHAPTER 5: LIFESTYLE DRUGS MARKET, BY FORM

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Form

    • 5.2. Tablets, Gel

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Oral Syrups

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Parenteral

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Creams

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Chewing Gums

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: LIFESTYLE DRUGS MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Hospital Pharmacy

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Drug Store

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Retail Store

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Online Pharmacy

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: LIFESTYLE DRUGS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Therapeutic Type

      • 7.2.3. Market Size and Forecast, By Form

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Lifestyle Drugs Market

        • 7.2.6.1. Market Size and Forecast, By Therapeutic Type
        • 7.2.6.2. Market Size and Forecast, By Form
        • 7.2.6.3. Market Size and Forecast, By Distribution Channel

      • 7.2.7. Canada Lifestyle Drugs Market

        • 7.2.7.1. Market Size and Forecast, By Therapeutic Type
        • 7.2.7.2. Market Size and Forecast, By Form
        • 7.2.7.3. Market Size and Forecast, By Distribution Channel

      • 7.2.8. Mexico Lifestyle Drugs Market

        • 7.2.8.1. Market Size and Forecast, By Therapeutic Type
        • 7.2.8.2. Market Size and Forecast, By Form
        • 7.2.8.3. Market Size and Forecast, By Distribution Channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Therapeutic Type

      • 7.3.3. Market Size and Forecast, By Form

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Lifestyle Drugs Market

        • 7.3.6.1. Market Size and Forecast, By Therapeutic Type
        • 7.3.6.2. Market Size and Forecast, By Form
        • 7.3.6.3. Market Size and Forecast, By Distribution Channel

      • 7.3.7. Germany Lifestyle Drugs Market

        • 7.3.7.1. Market Size and Forecast, By Therapeutic Type
        • 7.3.7.2. Market Size and Forecast, By Form
        • 7.3.7.3. Market Size and Forecast, By Distribution Channel

      • 7.3.8. Italy Lifestyle Drugs Market

        • 7.3.8.1. Market Size and Forecast, By Therapeutic Type
        • 7.3.8.2. Market Size and Forecast, By Form
        • 7.3.8.3. Market Size and Forecast, By Distribution Channel

      • 7.3.9. Spain Lifestyle Drugs Market

        • 7.3.9.1. Market Size and Forecast, By Therapeutic Type
        • 7.3.9.2. Market Size and Forecast, By Form
        • 7.3.9.3. Market Size and Forecast, By Distribution Channel

      • 7.3.10. UK Lifestyle Drugs Market

        • 7.3.10.1. Market Size and Forecast, By Therapeutic Type
        • 7.3.10.2. Market Size and Forecast, By Form
        • 7.3.10.3. Market Size and Forecast, By Distribution Channel

      • 7.3.11. Russia Lifestyle Drugs Market

        • 7.3.11.1. Market Size and Forecast, By Therapeutic Type
        • 7.3.11.2. Market Size and Forecast, By Form
        • 7.3.11.3. Market Size and Forecast, By Distribution Channel

      • 7.3.12. Rest Of Europe Lifestyle Drugs Market

        • 7.3.12.1. Market Size and Forecast, By Therapeutic Type
        • 7.3.12.2. Market Size and Forecast, By Form
        • 7.3.12.3. Market Size and Forecast, By Distribution Channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Therapeutic Type

      • 7.4.3. Market Size and Forecast, By Form

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Lifestyle Drugs Market

        • 7.4.6.1. Market Size and Forecast, By Therapeutic Type
        • 7.4.6.2. Market Size and Forecast, By Form
        • 7.4.6.3. Market Size and Forecast, By Distribution Channel

      • 7.4.7. Japan Lifestyle Drugs Market

        • 7.4.7.1. Market Size and Forecast, By Therapeutic Type
        • 7.4.7.2. Market Size and Forecast, By Form
        • 7.4.7.3. Market Size and Forecast, By Distribution Channel

      • 7.4.8. India Lifestyle Drugs Market

        • 7.4.8.1. Market Size and Forecast, By Therapeutic Type
        • 7.4.8.2. Market Size and Forecast, By Form
        • 7.4.8.3. Market Size and Forecast, By Distribution Channel

      • 7.4.9. South Korea Lifestyle Drugs Market

        • 7.4.9.1. Market Size and Forecast, By Therapeutic Type
        • 7.4.9.2. Market Size and Forecast, By Form
        • 7.4.9.3. Market Size and Forecast, By Distribution Channel

      • 7.4.10. Australia Lifestyle Drugs Market

        • 7.4.10.1. Market Size and Forecast, By Therapeutic Type
        • 7.4.10.2. Market Size and Forecast, By Form
        • 7.4.10.3. Market Size and Forecast, By Distribution Channel

      • 7.4.11. Thailand Lifestyle Drugs Market

        • 7.4.11.1. Market Size and Forecast, By Therapeutic Type
        • 7.4.11.2. Market Size and Forecast, By Form
        • 7.4.11.3. Market Size and Forecast, By Distribution Channel

      • 7.4.12. Malaysia Lifestyle Drugs Market

        • 7.4.12.1. Market Size and Forecast, By Therapeutic Type
        • 7.4.12.2. Market Size and Forecast, By Form
        • 7.4.12.3. Market Size and Forecast, By Distribution Channel

      • 7.4.13. Indonesia Lifestyle Drugs Market

        • 7.4.13.1. Market Size and Forecast, By Therapeutic Type
        • 7.4.13.2. Market Size and Forecast, By Form
        • 7.4.13.3. Market Size and Forecast, By Distribution Channel

      • 7.4.14. Rest of Asia Pacific Lifestyle Drugs Market

        • 7.4.14.1. Market Size and Forecast, By Therapeutic Type
        • 7.4.14.2. Market Size and Forecast, By Form
        • 7.4.14.3. Market Size and Forecast, By Distribution Channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Therapeutic Type

      • 7.5.3. Market Size and Forecast, By Form

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Lifestyle Drugs Market

        • 7.5.6.1. Market Size and Forecast, By Therapeutic Type
        • 7.5.6.2. Market Size and Forecast, By Form
        • 7.5.6.3. Market Size and Forecast, By Distribution Channel

      • 7.5.7. South Africa Lifestyle Drugs Market

        • 7.5.7.1. Market Size and Forecast, By Therapeutic Type
        • 7.5.7.2. Market Size and Forecast, By Form
        • 7.5.7.3. Market Size and Forecast, By Distribution Channel

      • 7.5.8. Saudi Arabia Lifestyle Drugs Market

        • 7.5.8.1. Market Size and Forecast, By Therapeutic Type
        • 7.5.8.2. Market Size and Forecast, By Form
        • 7.5.8.3. Market Size and Forecast, By Distribution Channel

      • 7.5.9. UAE Lifestyle Drugs Market

        • 7.5.9.1. Market Size and Forecast, By Therapeutic Type
        • 7.5.9.2. Market Size and Forecast, By Form
        • 7.5.9.3. Market Size and Forecast, By Distribution Channel

      • 7.5.10. Argentina Lifestyle Drugs Market

        • 7.5.10.1. Market Size and Forecast, By Therapeutic Type
        • 7.5.10.2. Market Size and Forecast, By Form
        • 7.5.10.3. Market Size and Forecast, By Distribution Channel

      • 7.5.11. Rest of LAMEA Lifestyle Drugs Market

        • 7.5.11.1. Market Size and Forecast, By Therapeutic Type
        • 7.5.11.2. Market Size and Forecast, By Form
        • 7.5.11.3. Market Size and Forecast, By Distribution Channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Allergan

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. BMS

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Eli Lilly

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Galderma

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Merck

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Pfizer

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Novartis

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. AstraZeneca,

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Sanofi

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Valeant Pharmaceuticals

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. Johnson And Johnson

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

    • 9.12. Teva Pharmaceutical Industries Ltd.

      • 9.12.1. Company Overview

      • 9.12.2. Key Executives

      • 9.12.3. Company Snapshot

      • 9.12.4. Operating Business Segments

      • 9.12.5. Product Portfolio

      • 9.12.6. Business Performance

      • 9.12.7. Key Strategic Moves and Developments

    • 9.13. Amgen Inc.

      • 9.13.1. Company Overview

      • 9.13.2. Key Executives

      • 9.13.3. Company Snapshot

      • 9.13.4. Operating Business Segments

      • 9.13.5. Product Portfolio

      • 9.13.6. Business Performance

      • 9.13.7. Key Strategic Moves and Developments

    • 9.14. Biocon Limited

      • 9.14.1. Company Overview

      • 9.14.2. Key Executives

      • 9.14.3. Company Snapshot

      • 9.14.4. Operating Business Segments

      • 9.14.5. Product Portfolio

      • 9.14.6. Business Performance

      • 9.14.7. Key Strategic Moves and Developments

    • 9.15. Dr. Reddy's Laboratories.

      • 9.15.1. Company Overview

      • 9.15.2. Key Executives

      • 9.15.3. Company Snapshot

      • 9.15.4. Operating Business Segments

      • 9.15.5. Product Portfolio

      • 9.15.6. Business Performance

      • 9.15.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL LIFESTYLE DRUGS MARKET, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL LIFESTYLE DRUGS MARKET FOR OBESITY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL LIFESTYLE DRUGS MARKET FOR WOMEN’S HEALTH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL LIFESTYLE DRUGS MARKET FOR INSOMNIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL LIFESTYLE DRUGS MARKET FOR SEXUAL DYSFUNCTION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL LIFESTYLE DRUGS MARKET FOR DERMATOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL LIFESTYLE DRUGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL LIFESTYLE DRUGS MARKET, BY FORM, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL LIFESTYLE DRUGS MARKET FOR TABLETS, GEL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL LIFESTYLE DRUGS MARKET FOR ORAL SYRUPS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL LIFESTYLE DRUGS MARKET FOR PARENTERAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL LIFESTYLE DRUGS MARKET FOR CREAMS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL LIFESTYLE DRUGS MARKET FOR CHEWING GUMS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL LIFESTYLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL LIFESTYLE DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL LIFESTYLE DRUGS MARKET FOR DRUG STORE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL LIFESTYLE DRUGS MARKET FOR RETAIL STORE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. GLOBAL LIFESTYLE DRUGS MARKET FOR ONLINE PHARMACY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. GLOBAL LIFESTYLE DRUGS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. NORTH AMERICA LIFESTYLE DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. NORTH AMERICA LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 22. NORTH AMERICA LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 23. NORTH AMERICA LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 24. U.S. LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 25. U.S. LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 26. U.S. LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 27. CANADA LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 28. CANADA LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 29. CANADA LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 30. MEXICO LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 31. MEXICO LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 32. MEXICO LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 33. EUROPE LIFESTYLE DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 34. EUROPE LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 35. EUROPE LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 36. EUROPE LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 37. FRANCE LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 38. FRANCE LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 39. FRANCE LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 40. GERMANY LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 41. GERMANY LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 42. GERMANY LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 43. ITALY LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 44. ITALY LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 45. ITALY LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 46. SPAIN LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 47. SPAIN LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 48. SPAIN LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 49. UK LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 50. UK LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 51. UK LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 52. RUSSIA LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 53. RUSSIA LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 54. RUSSIA LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 55. REST OF EUROPE LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 56. REST OF EUROPE LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 57. REST OF EUROPE LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 58. ASIA-PACIFIC LIFESTYLE DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 59. ASIA-PACIFIC LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 60. ASIA-PACIFIC LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 61. ASIA-PACIFIC LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 62. CHINA LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 63. CHINA LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 64. CHINA LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 65. JAPAN LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 66. JAPAN LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 67. JAPAN LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 68. INDIA LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 69. INDIA LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 70. INDIA LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 71. SOUTH KOREA LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 72. SOUTH KOREA LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 73. SOUTH KOREA LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 74. AUSTRALIA LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 75. AUSTRALIA LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 76. AUSTRALIA LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 77. THAILAND LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 78. THAILAND LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 79. THAILAND LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 80. MALAYSIA LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 81. MALAYSIA LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 82. MALAYSIA LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 83. INDONESIA LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 84. INDONESIA LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 85. INDONESIA LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 86. REST OF ASIA PACIFIC LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 87. REST OF ASIA PACIFIC LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 88. REST OF ASIA PACIFIC LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 89. LAMEA LIFESTYLE DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 90. LAMEA LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 91. LAMEA LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 92. LAMEA LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 93. BRAZIL LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 94. BRAZIL LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 95. BRAZIL LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 96. SOUTH AFRICA LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 97. SOUTH AFRICA LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 98. SOUTH AFRICA LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 99. SAUDI ARABIA LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 100. SAUDI ARABIA LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 101. SAUDI ARABIA LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 102. UAE LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 103. UAE LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 104. UAE LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 105. ARGENTINA LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 106. ARGENTINA LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 107. ARGENTINA LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 108. REST OF LAMEA LIFESTYLE DRUGS, BY THERAPEUTIC TYPE, 2025-2033 ($MILLION)
  • TABLE 109. REST OF LAMEA LIFESTYLE DRUGS, BY FORM, 2025-2033 ($MILLION)
  • TABLE 110. REST OF LAMEA LIFESTYLE DRUGS, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 111. ALLERGAN: KEY EXECUTIVES
  • TABLE 112. ALLERGAN: COMPANY SNAPSHOT
  • TABLE 113. ALLERGAN: OPERATING SEGMENTS
  • TABLE 114. ALLERGAN: PRODUCT PORTFOLIO
  • TABLE 115. ALLERGAN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. BMS: KEY EXECUTIVES
  • TABLE 117. BMS: COMPANY SNAPSHOT
  • TABLE 118. BMS: OPERATING SEGMENTS
  • TABLE 119. BMS: PRODUCT PORTFOLIO
  • TABLE 120. BMS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. ELI LILLY: KEY EXECUTIVES
  • TABLE 122. ELI LILLY: COMPANY SNAPSHOT
  • TABLE 123. ELI LILLY: OPERATING SEGMENTS
  • TABLE 124. ELI LILLY: PRODUCT PORTFOLIO
  • TABLE 125. ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126. GALDERMA: KEY EXECUTIVES
  • TABLE 127. GALDERMA: COMPANY SNAPSHOT
  • TABLE 128. GALDERMA: OPERATING SEGMENTS
  • TABLE 129. GALDERMA: PRODUCT PORTFOLIO
  • TABLE 130. GALDERMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 131. MERCK: KEY EXECUTIVES
  • TABLE 132. MERCK: COMPANY SNAPSHOT
  • TABLE 133. MERCK: OPERATING SEGMENTS
  • TABLE 134. MERCK: PRODUCT PORTFOLIO
  • TABLE 135. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 136. PFIZER: KEY EXECUTIVES
  • TABLE 137. PFIZER: COMPANY SNAPSHOT
  • TABLE 138. PFIZER: OPERATING SEGMENTS
  • TABLE 139. PFIZER: PRODUCT PORTFOLIO
  • TABLE 140. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. NOVARTIS: KEY EXECUTIVES
  • TABLE 142. NOVARTIS: COMPANY SNAPSHOT
  • TABLE 143. NOVARTIS: OPERATING SEGMENTS
  • TABLE 144. NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 145. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. ASTRAZENECA,: KEY EXECUTIVES
  • TABLE 147. ASTRAZENECA,: COMPANY SNAPSHOT
  • TABLE 148. ASTRAZENECA,: OPERATING SEGMENTS
  • TABLE 149. ASTRAZENECA,: PRODUCT PORTFOLIO
  • TABLE 150. ASTRAZENECA,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. SANOFI: KEY EXECUTIVES
  • TABLE 152. SANOFI: COMPANY SNAPSHOT
  • TABLE 153. SANOFI: OPERATING SEGMENTS
  • TABLE 154. SANOFI: PRODUCT PORTFOLIO
  • TABLE 155. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 156. VALEANT PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 157. VALEANT PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 158. VALEANT PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 159. VALEANT PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 160. VALEANT PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 161. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 162. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 163. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 164. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 165. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 166. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 167. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 168. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 169. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 170. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 171. AMGEN INC.: KEY EXECUTIVES
  • TABLE 172. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 173. AMGEN INC.: OPERATING SEGMENTS
  • TABLE 174. AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 175. AMGEN INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 176. BIOCON LIMITED: KEY EXECUTIVES
  • TABLE 177. BIOCON LIMITED: COMPANY SNAPSHOT
  • TABLE 178. BIOCON LIMITED: OPERATING SEGMENTS
  • TABLE 179. BIOCON LIMITED: PRODUCT PORTFOLIO
  • TABLE 180. BIOCON LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 181. DR. REDDY'S LABORATORIES.: KEY EXECUTIVES
  • TABLE 182. DR. REDDY'S LABORATORIES.: COMPANY SNAPSHOT
  • TABLE 183. DR. REDDY'S LABORATORIES.: OPERATING SEGMENTS
  • TABLE 184. DR. REDDY'S LABORATORIES.: PRODUCT PORTFOLIO
  • TABLE 185. DR. REDDY'S LABORATORIES.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL LIFESTYLE DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL LIFESTYLE DRUGS MARKET
  • FIGURE 3. SEGMENTATION LIFESTYLE DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN LIFESTYLE DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALLIFESTYLE DRUGS MARKET
  • FIGURE 11. LIFESTYLE DRUGS MARKET SEGMENTATION, BY BY THERAPEUTIC TYPE
  • FIGURE 12. LIFESTYLE DRUGS MARKET FOR OBESITY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. LIFESTYLE DRUGS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. LIFESTYLE DRUGS MARKET FOR INSOMNIA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. LIFESTYLE DRUGS MARKET FOR SEXUAL DYSFUNCTION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. LIFESTYLE DRUGS MARKET FOR DERMATOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. LIFESTYLE DRUGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. LIFESTYLE DRUGS MARKET SEGMENTATION, BY BY FORM
  • FIGURE 19. LIFESTYLE DRUGS MARKET FOR TABLETS, GEL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. LIFESTYLE DRUGS MARKET FOR ORAL SYRUPS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. LIFESTYLE DRUGS MARKET FOR PARENTERAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. LIFESTYLE DRUGS MARKET FOR CREAMS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. LIFESTYLE DRUGS MARKET FOR CHEWING GUMS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. LIFESTYLE DRUGS MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 25. LIFESTYLE DRUGS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. LIFESTYLE DRUGS MARKET FOR DRUG STORE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 27. LIFESTYLE DRUGS MARKET FOR RETAIL STORE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 28. LIFESTYLE DRUGS MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 29. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 30. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 31. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 32. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 33. COMPETITIVE DASHBOARD
  • FIGURE 34. COMPETITIVE HEATMAP: LIFESTYLE DRUGS MARKET
  • FIGURE 35. TOP PLAYER POSITIONING, 2024
  • FIGURE 36. ALLERGAN: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. ALLERGAN: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. ALLERGAN: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. BMS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. BMS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. BMS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. ELI LILLY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. ELI LILLY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. ELI LILLY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. GALDERMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. GALDERMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. GALDERMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. MERCK: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. MERCK: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. MERCK: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. PFIZER: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. PFIZER: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. PFIZER: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. NOVARTIS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. NOVARTIS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. NOVARTIS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. ASTRAZENECA,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. ASTRAZENECA,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. ASTRAZENECA,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 60. SANOFI: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 61. SANOFI: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 62. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 63. VALEANT PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 64. VALEANT PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 65. VALEANT PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 66. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 67. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 68. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 69. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 70. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 71. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 72. AMGEN INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 73. AMGEN INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 74. AMGEN INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 75. BIOCON LIMITED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 76. BIOCON LIMITED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 77. BIOCON LIMITED: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 78. DR. REDDY'S LABORATORIES.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 79. DR. REDDY'S LABORATORIES.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 80. DR. REDDY'S LABORATORIES.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Lifestyle Drugs Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved